U.S. flag

An official website of the United States government

NM_001122659.3(EDNRB):c.1143dup (p.Asn382Ter) AND EDNRB-related disorder

Germline classification:
Likely pathogenic (1 submission)
Last evaluated:
Mar 16, 2023
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003408492.4

Allele description [Variation Report for NM_001122659.3(EDNRB):c.1143dup (p.Asn382Ter)]

NM_001122659.3(EDNRB):c.1143dup (p.Asn382Ter)

Genes:
EDNRB-AS1:EDNRB antisense RNA 1 [Gene - HGNC]
EDNRB:endothelin receptor type B [Gene - OMIM - HGNC]
Variant type:
Duplication
Cytogenetic location:
13q22.3
Genomic location:
Preferred name:
NM_001122659.3(EDNRB):c.1143dup (p.Asn382Ter)
HGVS:
  • NC_000013.11:g.77899911dup
  • NG_011630.3:g.79814dup
  • NM_000115.5:c.1143dup
  • NM_001122659.3:c.1143dupMANE SELECT
  • NM_001201397.2:c.1412dup
  • NM_003991.4:c.1143dup
  • NP_000106.1:p.Asn382Ter
  • NP_001116131.1:p.Asn382Ter
  • NP_001188326.1:p.Asn472Ter
  • NP_001188326.1:p.Asn472Terfs
  • NP_003982.1:p.Asn382Ter
  • NC_000013.10:g.78474046dup
  • NM_000115.4:c.1143dupT
  • NM_001201397.1:c.1413dup
Protein change:
N382*
Molecular consequence:
  • NM_001201397.2:c.1412dup - frameshift variant - [Sequence Ontology: SO:0001589]
  • NM_000115.5:c.1143dup - nonsense - [Sequence Ontology: SO:0001587]
  • NM_001122659.3:c.1143dup - nonsense - [Sequence Ontology: SO:0001587]
  • NM_001201397.2:c.1412dup - nonsense - [Sequence Ontology: SO:0001587]
  • NM_003991.4:c.1143dup - nonsense - [Sequence Ontology: SO:0001587]

Condition(s)

Name:
EDNRB-related disorder
Synonyms:
EDNRB-related condition; EDNRB-Related Disorders
Identifiers:

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV004110183PreventionGenetics, part of Exact Sciences
criteria provided, single submitter

(ACMG Guidelines, 2015)
Likely pathogenic
(Mar 16, 2023)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee.

Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.

PubMed [citation]
PMID:
25741868
PMCID:
PMC4544753

Details of each submission

From PreventionGenetics, part of Exact Sciences, SCV004110183.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

The EDNRB c.1143dupT variant is predicted to result in premature protein termination (p.Asn382*). To our knowledge, this variant has not been reported in the literature or in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Nonsense variants in EDNRB are expected to be pathogenic. This variant is interpreted as likely pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 1, 2024